Further studies showed that a subpopulation of CD200+ CAFs exhibited increased gefitinib sensitivity due to an enhanced pro-apoptotic effect of gefitinib on cancer cells and that downregulation of CD200 expression deprived CAFs of their sensitizing ability. The gene discussed is CD200; the disease is cancer.